Europe's medicines regulator on Friday recommended granting marketing authorisation to mCombriax, making Moderna's messenger RNA vaccine the world's first combined shot for ...
This prompts a reassessment of the stock’s value to determine if this represents a genuine opportunity or a potential trap.
The company has had its ups -- the approval of its respiratory syncytial virus (RSV) vaccine back in 2024 -- and its downs -- the failure of its cytomegalovirus (CMV) vaccine candidate in a phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results